Bayerische Motoren Werke ADR (BMWYY)

In clinical-stage biotechnology, the central challenge is rarely scientific discovery. It is capital. Advancing multiple therapeutic candidates through preclinical work, clinical trials, and regulatory approval requires sustained funding, and traditional financing routes often come at the cost of dilution or loss of asset control. With biotech capital markets remaining selective and the IPO window constrained, alternative models that preserve shareholder value while advancing pipelines are gaining traction.

BioMedWire Editorial Coverage: The ability to accurately detect drug and alcohol intoxication has long been a persistent challenge across industries, from law enforcement and workplace safety to healthcare and public health management. Traditional methods such as breathalyzers, blood tests and urine screenings are often limited by their invasiveness, delayed results or inability to assess real-time impairment, particularly in cases involving multiple substances. As patterns of substance use evolve and the societal costs of impaired behavior continue to rise, the demand for faster, more scalable and noninvasive diagnostic solutions is becoming increasingly urgent. MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) ( Profile ) is advancing a novel approach that leverages artificial intelligence (“AI”) and voice analysis to predict intoxication from short speech samples. By focusing on the human voice as a measurable indicator of internal physiological and cognitive states, the company is working to develop a platform capable of detecting impairment across a range of substances in real-time. This approach not only addresses a critical gap in existing detection methods but also reflects a broader shift toward AI-driven, noninvasive diagnostics with the potential to transform regulatory enforcement, workplace safety and public health outcomes. MindBio joins other key companies operating at the forefront of health, AI and diagnostics technologies, including HeartFlow Inc. (NASDAQ: HTFL), Recursion Pharmaceuticals Inc. (NASDAQ: RXRX), Tempus AI Inc. (NASDAQ: TEM) and…

BioMedWire Editorial Coverage: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (“CNS”). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: OTLC) ( Profile ), are working within a broader industry shift toward advanced delivery platforms designed to bypass traditional barriers and facilitate rapid, targeted access to the brain. Oncotelic’s approach, which includes a proprietary intranasal nose-to-brain (“N2B”) system that enables rapid therapeutic delivery, reflects a growing recognition that solving CNS delivery, not just drug discovery, may be key to unlocking the next generation of therapies. Oncotelic joins a group of leading biopharma companies focused on cutting-edge therapeutic platforms and large-scale drug development in a range of treatment areas, including Biogen Inc. (NASDAQ: BIIB), Moderna Inc. (NASDAQ: MRNA), CytoDyn Inc. (OTCQB: CYDY) and…

BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (“T2DM”) have become two of the most pressing healthcare challenges worldwide, driving rising rates of cardiovascular disease, fatty liver disease, kidney complications and escalating healthcare costs. What began as a niche class of diabetes medications has evolved into one of the most transformative therapeutic categories in modern medicine, with GLP-1 receptor agonists now reshaping obesity treatment, metabolic care and potentially even neurodegenerative disease management. Against this backdrop, SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF), ( Profile ) through its subsidiary GlucaPharm Inc., is advancing a differentiated next-generation GLP-1 platform centered on GEP-44, a novel triple agonist peptide designed to improve efficacy, tolerability and delivery flexibility in one of the fastest-growing pharmaceutical markets in history. SureNano is one of the emerging microcap companies operating in the GLP space, forming part of a group of companies leading the way in the GLP-1 space, including Eli Lilly and Company (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), Amgen Inc. (NASDAQ: AMGN) and…

Limo SF VIP has announced the availability of their executive chauffeur service for the summer conference season.

Last week, the U.S. Department of Justice announced a plan to tackle tech-driven fraud in the health care system on the West Coast . The initiative will focus on California, Arizona and Nevada. Their investigations will target fraudulent schemes, especially those executed by digital health firms.

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, announced a strategic initiative to explore ibogaine-based therapeutics for traumatic brain injury and related neuropsychiatric conditions, including the filing of a provisional U.S. patent application covering compositions and methods using ibogaine and related compounds to treat TBI, PTSD and associated disorders.

The media is awash with news that a cruise ship, called MV Hondius, has suffered an outbreak of hantavirus . Three fatalities have occurred, with one victim confirmed to have died from this infection. Many people are wondering what this infection is and what they can do to stay safe or what they can do in case they are infected. We provide an explainer of the basics you need to know about this virus.

Dolby Laboratories’ first quarter saw stronger-than-expected revenue and non-GAAP profit, yet the market reacted negatively to the results. Management pointe...

Limo SF VIP has announced an expansion to their service range, and will now provide luxury long-distance shuttle services from San Francisco to Los Angeles.

BlackBerry’s surge looks more like an early-stage re‑rating on a credible software and embedded‑systems thesis than a fleeting meme‑style pop.

Xiaomi is laying the groundwork for a European push, having opened an EV research and design center in Munich last year. The facility, headed by former BMW executive Rudolf Dittrich, focuses on adapting Xiaomi’s vehicles to European safety standards, charging infrastructure, and consumer expectations. Germany is slated to be the company’s debut overseas market when international sales begin in 2027.

Immunotherapy has emerged as a key weapon in the fight against cancer. However, nearly 80% of patients either don’t respond to these treatments or they become unresponsive after initially responding to the immunotherapy. The scientific community has been grappling with how to improve response rates, and a new study uncovering how cancer cells reprogram our immune cells to support cancer growth could provide a key .

Oragenics (NYSE American: OGEN) announced active enrollment at a second site in its Phase IIa clinical trial evaluating ONP-002 for concussion and mild traumatic brain injury, with four patients already dosed at its initial Australian site, as the company progresses toward a planned data readout by year-end 2026.

Dolby (DLB) Q2 2026 Earnings Call Transcript

Audio and video technology company Dolby Laboratories (NYSE:DLB) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 7.1% ye...

Mooresville, NC - AutoTechnic reinforces its position as a dedicated German automotive specialist, focusing exclusively on BMW, MINI, and Mercedes-Benz vehicles. Located in downtown Mooresville, AutoTechnic provides comprehensive repair and maintenance solutions designed to support long-term vehicle performance and reliability.

New research has mapped how breast tissues change as women age. The findings help to explain why breast cancer cases are higher in older women, and this could potentially help in finding new ways to fight this disease.

During a recent House hearing conducted by the Ways and Means Committee, hospital CEOs were put on the spot over the inexplicably high facility fees that they charge. GOP members of the committee accused the hospitals of taking advantage of the healthcare system and of overcharging patients.

Telomir Pharmaceuticals (NASDAQ: TELO), a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for Telomir-Zn to treat advanced or metastatic triple-negative breast cancer. The clearance enables initiation of a first-in-human Phase 1/2 clinical trial designed to evaluate safety, dosing and preliminary antitumor activity, supported by preclinical pharmacology, toxicology and biomarker data as the Company advances its lead candidate toward clinical development.

Beijing, China, April 30, 2026 -- At Auto China 2026, Reach officially unveiled its full-stack product portfolio designed to accelerate the intelligent evolution of AI vehicles. Industry leaders and experts, along with executives and representatives from Honda, Toyota, FAW, Geely, GAC, Dongfeng Voyah, FAW Jiefang, BMW, Volkswagen CARIAD, Chery, Nissan, Mazda, Hitachi Astemo, Bosch, UAES, ZTE Microelectronics and other global OEMs and industry partners, visited the booth for in-depth discussions on the future of AI-powered mobility and intelligent vehicle evolution.

Wuhu, Anhui, China, April 30, 2026 -- LUXEED International successfully held the “LUXEED Prototype Private Preview”, an exclusive session under the brand’s premium themed campaign ‘“I” Drive, You Enjoy’, from April 25 to 26. The event brought together over 300 key dealers from more than a dozen countries and regions across Europe, right-hand-drive markets, and the Middle East, to explore LUXEED’s upcoming product portfolio and discuss new opportunities for the brand’s global development.

ARMADALE, WA - April 29, 2026 - Triggs Garage, a European vehicle specialist workshop based in Armadale, is bringing decades of European-born automotive expertise to Perth drivers of BMW, Audi, Mercedes-Benz, Volkswagen, and other European marques. Founded in the United Kingdom in 1977 and established in Western Australia in 2018, the workshop combines deep manufacturer-trained knowledge with current-generation diagnostic equipment, giving Perth owners of premium European cars a dealer-level alternative to franchise servicing.

Limo SF VIP ((888) 888-0195) has expanded their offerings to include luxury sedan chauffeur services in the San Francisco area.

ARMR Sciences completed a private placement financing with strategic and institutional investors, with Joseph Gunnar & Co., LLC acting as placement agent, as the company advances toward human trials for its fentanyl vaccine. Backed by the U.S. Department of War, the vaccine is designed to prevent fatal overdoses and address threats from substances such as fentanyl, supporting continued development and clinical progression.